Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue

by Roseboom IC, Thijssen B, Rosing H, Alves F, Younis BM, Musa AM, Beijnen JH, Dorlo TPC. Journal of Chromatography B 2022; 1211:123494. doi: 10.1016/j.jchromb.2022.123494

Summary: Paromomycin is used to treat multiple clinical presentations of the neglected tropical disease leishmaniasis, including post-kala-azar dermal leishmaniasis, in which Leishmania parasites divide and reside in the skin. Little is known about the distribution of antileishmanial drugs in skin of patients after systemic treatment. Target-site PK data are urgently needed to further optimize and rationalize therapy. The authors present a target-site bioanalytical method to quantify paromomycin in skin tissue of patients with post-kala-azar dermal leishmaniasis from Sudan, using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. This bioanalytical assay performed within approved European Medicines Agency acceptance criteria for accuracy and precision, and paromomycin was accurately quantified in skin of post-kala-azar dermal leishmaniasis patients originating from clinical trials in Sudan.

The post Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue first appeared on DNDi.